18 studies found for:    tas-102
Show Display Options
Rank Status Study
1 Recruiting Phase I Study of SGI-110 With Irinotecan Followed by Randomized Phase II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Previously Treated Metastatic Colorectal Cancer
Condition: Previously Treated Metastatic Colorectal Cancer
Interventions: Drug: SGI-110;   Drug: Irinotecan;   Drug: regorafenib;   Drug: TAS-102
2 Not yet recruiting Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases
Conditions: Colon Cancer;   Rectal Cancer;   Liver Metastases
Interventions: Drug: Tas-102;   Device: SIR-Sphere
3 Completed Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPI
Condition: Advanced Solid Tumors (Excluding Breast Cancer)
Interventions: Drug: TAS-102 tablets;   Drug: TAS-102 oral solution
4 Active, not recruiting Study of the Mass Balance of Oral FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors
Condition: Advanced Solid Tumors
Interventions: Drug: TAS-102 with a light tracer dose of [14C]FTD;   Drug: TAS-102 with a light tracer dose of [14C] TPI;   Drug: TAS-102 tablets
5 Active, not recruiting A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic Impairment
Condition: Advanced Solid Tumors
Intervention: Drug: TAS-102
6 Recruiting Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Intervention: Drug: TAS-102 and Bevacizumab
7 Recruiting A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With Colorectal Cancer
Condition: Colorectal Cancer
Intervention: Drug: panitumumab, TAS-102
8 Recruiting Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer
Condition: Refractory Metastatic Gastric Cancer
Interventions: Drug: TAS-102;   Drug: Placebo
9 Recruiting A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment
Condition: Advanced Solid Tumors
Intervention: Drug: TAS-102
10 Recruiting A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.
Condition: Advanced Gastrointestinal Tumors
Interventions: Drug: TAS-102;   Drug: CPT-11;   Drug: Bevacizumab
11 Completed Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid Tumors
Condition: Advanced Solid Tumors (Excluding Breast Cancer)
Interventions: Drug: TAS-102;   Drug: Placebo
12 Active, not recruiting A Phase I Study of TAS-102 in Solid Tumors
Condition: Advanced or Metastatic Solid Tumors
Intervention: Drug: TAS-102
13 Active, not recruiting Study of TAS-102 in Patients With Metastatic Colorectal Cancer in Asia
Condition: Colorectal Cancer
Interventions: Drug: TAS-102;   Drug: Placebo
14 Active, not recruiting Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Condition: Colorectal Cancer
Interventions: Drug: TAS-102;   Drug: Placebo
15 Active, not recruiting Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD Alone
Condition: Advanced Solid Tumors
Interventions: Drug: TAS-102;   Drug: Trifluridine
16 Terminated A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy
Condition: Small Cell Lung Cancer (SCLC)
Interventions: Drug: TAS-102;   Drug: Amrubicin (Japan);   Drug: Topotecan (Japan/Europe)
17 Approved for marketing Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer
Condition: Colorectal Cancer Metastatic
Intervention: Drug: TAS-102
18 Recruiting A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy
Condition: Metastatic Colorectal Cancer
Interventions: Drug: Trifluridine/tipiracil hydrochloride (S 95005);   Drug: Capecitabine;   Drug: Bevacizumab

Indicates status has not been verified in more than two years